Cimetidine and Chlorpheniramine in the Treatment of Psoriasis

Goerz, G; Runne, U; Kurka, M; Schafer, Jeremy A.; Brendel, E

doi:10.1159/000249845

Cited by 10 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, several authors have reported a worsening of psoriasis after treatment.14,16, 17 However, in a recent long-term trial of ranitidine as treat¬ ment for psoriasis, in which six patients received a 4-month course of therapy, the lesions in four patients markedly im¬ proved and the lesions in two patients remained unchanged.18 Three of the four patients whose lesions improved experi¬ enced an initial deterioration of the disease. In fact, several authors have reported a worsening of psoriasis after treatment.14,16, 17 However, in a recent long-term trial of ranitidine as treat¬ ment for psoriasis, in which six patients received a 4-month course of therapy, the lesions in four patients markedly im¬ proved and the lesions in two patients remained unchanged.18 Three of the four patients whose lesions improved experi¬ enced an initial deterioration of the disease.…”

Section: Commentmentioning

confidence: 99%

Cimetidine as Therapy for Treatment-Resistant Psoriasis in a Patient With Acquired Immunodeficiency Syndrome

Stashower

Yeager²,

Smith³

et al. 1993

Arch Dermatol

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 99%

Cimetidine as Therapy for Treatment-Resistant Psoriasis in a Patient With Acquired Immunodeficiency Syndrome

Stashower

Yeager²,

Smith³

et al. 1993

Arch Dermatol

View full text Add to dashboard Cite

Ranitidine for Improvement of Treatment-Resistant Psoriasis

Nielsen¹

1991

Arch Dermatol

View full text Add to dashboard Cite

RE. Chrysotherapy in psoriatic arthritis: efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum. 1978;21:513-515. 6. Richter MB, Kinsella P, Corbett M. Gold in psoriatic arthropathy. Ann Rheum Dis. 1980;39:279-280. 7. Dequeker J, Gevers G. An open study on the efficacy and safety of auranofin in treating psoriatic arthritis. Scand J Rheum. 1986;2(suppl 63):85\x=req-\ 95. 8. Carette S, Calin A, McCafferty J, Wallin B, et al. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum. 1989;32:158-165. 9. Naranjo CA, Busto U, Sellers EM, Sandor P, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. PsoriasisTo the Editor.\p=m-\Our studies of the effect of the histamine2 (H2) receptor antagonist, ranitidine, in patients with trauma-and blood transfusion-induced immunosuppression, in patients with multiple myeloma, and in patients with human immunodeficiency virus infection,1 have included a few patients with psoriatic lesions. Some of these patients who were treated with the active drug showed improvement in psoriatic disease, but with recurrence within a few weeks after the therapy was discontinued. Based on these observations, and despite previous randomized, placebo-controlled studies of short-term treatment (28 days) with another H2 receptor antagonist, cimetidine, which had shown no beneficial effect,2 an open pilot study of the effect of long-term (4 months) treatment with ranitidine in patients with different forms of psoriasis was initiated.

show abstract

Psoriasis

Orfanos

Garbe

2002

Therapie Der Hautkrankheiten

View full text Add to dashboard Cite

Cimetidine and Chlorpheniramine in the Treatment of Psoriasis

Cited by 10 publications

References 8 publications

Cimetidine as Therapy for Treatment-Resistant Psoriasis in a Patient With Acquired Immunodeficiency Syndrome

Cimetidine as Therapy for Treatment-Resistant Psoriasis in a Patient With Acquired Immunodeficiency Syndrome

Ranitidine for Improvement of Treatment-Resistant Psoriasis

Psoriasis

Contact Info

Product

Resources

About